Loosdrecht, A. V. D., Drouet, E. W., Platzbecker, U., Holderried, T. A., Elssen, J. V., Giagounidis, A., Lehmann, S., Cloos, J., Zeeburg, H. V., Rovers, J., Karlsson-Parra, A., Mughal, T., Gjertsen, B. (2025). Post-remission immunotherapy with vididencel for a measurable residual disease defined high-risk sub-group of adult patients with Acute Myeloid Leukemia in first complete hematological remission: Updated results of the european advance II study demonstrate robust safety, relapse-free and overall survival benefit.. Blood. https://doi.org/10.1182/blood-2025-1647